
1	Epidemiology of Bone and Soft Tissue Sarcomas	
	Logan G. Spector, Julie A. Ross, Rajaram Nagarajan	
1.1	Descriptive Epidemiology of Bone Tumors	1
1.2	Worldwide Statistics	1
1.3	North American Statistics	3
1.4	Mortality and Survivorship	4
1.5	Etiology of Bone Sarcomas	5
1.6	Bone Sarcomas: Future Directions	7
1.7	Epidemiology of Soft Tissue Sarcomas	7
	References	9

2	Pathologic and Molecular Techniques Used in the Diagnosis and Treatment Planning of Sarcomas	
	Timothy Triche, Deborah Schofield	
2.1	Introduction	13
2.2	Standard Histopathology	14
	2.2.1 Light Microscopy	14
	2.2.2 Immunohistochemistry	15
	2.2.3 Electron Microscopy	16
2.3	Cytogenetics	16
	2.3.1 Classical Cytogenetic Analysis	16
	2.3.2 In-Situ Hybridization	18
	2.3.3 Spectral Karyotyping	19
	2.3.4 Comparative Genomic Hybridization	20
2.4	Molecular Genetic Techniques	20
	2.4.1 Introduction	20
	2.4.2 PCR and Q-PCR	20
	2.4.3 Microarrays	23
	2.4.4 Proteomics	27
	2.4.5 Conclusion	30
	References	31

Contents

3 Diagnostic Imaging of Pediatric Bone and Soft Tissue Sarcomas

Thomas D. Henry, Mary E. McCarville,
Fredric A. Hoffer

3.1	Introduction	35
3.2	Initial Evaluation of Bone and Soft Tissue Sarcomas	35
3.3	Imaging Techniques for Evaluating the Primary Tumor	37
3.4	Staging	38
	3.4.1 Local Extent of the Tumor	38
	3.4.2 Detection of Metastatic Disease	40
3.5	Criteria for Evaluating Treatment Response	41
3.6	Outcome Criteria	43
3.7	Biopsy of the Primary Lesion	43
3.8	Imaging Characteristics of Specific Tumors	44
	3.8.1 Bone Sarcomas	44
	3.8.1.1 Osteosarcoma	44
	3.8.1.2 Chondrosarcoma	48
	3.8.1.3 Ewing Sarcoma of Bone	48
	3.8.2 Soft Tissue Sarcomas	51
	3.8.2.1 Differentiating Benign from Malignant Soft Tissue Lesions	51
	3.8.2.2 Soft Tissue Ewing Sarcoma Family of Tumors	52
	3.8.2.3 Rhabdomyosarcoma	54
	3.8.2.4 Non-rhabdomyosarcoma Soft Tissue Sarcomas	61
	3.8.2.4.1 Synovial Sarcoma	61
	3.8.2.4.2 Congenital Fibrosarcoma	62
	3.8.2.4.3 Hemangiopericytoma	63
	3.8.2.4.4 Malignant Peripheral Nerve Sheath Tumors (MPNST)	65
3.9	Post-treatment Imaging Concerns	66
3.10	Radiofrequency Ablation	66
	References	67

4 Local Control Issues in Pediatric Bone and Soft Tissue Sarcomas

John C. Breneman, David Rodeberg,
Ruth F. Lavigne, Ken Brown, Eugene S. Wiener

4.1	Significance of Local Control in Pediatric Sarcomas	71
4.2	Background to Local Control Modalities	72
4.2.1	Patterns of Tumor Growth	72
4.2.2	Surgery	72
4.2.2.1	Biopsy Guidelines	72
4.2.2.2	Surgical Margins	72
4.2.3	Radiation Therapy	73
4.2.3.1	Types of Radiation	73
4.2.3.2	Techniques of Radiotherapy	73
4.2.3.3	Treatment Morbidity	74
4.2.4	Combined Surgery and Radiotherapy for Local Control	74
4.2.5	Chemotherapy for Local Control	75
4.3	Ewing's Sarcoma	75
4.3.1	Surgery for Ewing's Sarcoma	75
4.3.2	Radiation Therapy for Ewing's Sarcoma	76
4.3.2.1	Radiotherapy Treatment Factors	76
4.4	Rhabdomyosarcoma	77
4.4.1	Surgery for Rhabdomyosarcoma	77
4.4.2	Radiotherapy for Rhabdomyosarcoma	78
4.4.3	Site Specific Approaches to Local Control	79
4.4.3.1	Orbit and Head & Neck	79
4.4.3.2	Genitourinary: Bladder/Prostate	79
4.4.3.3	Vagina and Uterine Sites	80
4.4.3.4	Paratestes	80
4.4.3.5	Extremity	80
4.4.3.6	Trunk	81
4.5	Non-Rhabdomyosarcomatous Soft Tissue Sarcomas	81
4.5.1	Surgery for Non-Rhabdo Soft Tissue Sarcomas	81
4.5.2	Radiotherapy for Non-Rhabdo Soft Tissue Sarcomas	82
4.6	Osteosarcoma	83
4.6.1	Surgery for Osteosarcoma	83
4.6.2	Radiotherapy for Osteosarcoma	84
	References	84

5 Drug Discovery in Pediatric Bone and Soft Tissue Sarcomas Using In Vivo Models

Jennifer K. Peterson, Peter J. Houghton

5.1	Introduction	89
5.2	Pediatric Tumor Models	90

5.3	General Criteria for Selecting Appropriate Models	91
5.4	Expression Profiles	91
5.5	Criteria for Selecting RMS Xenografts for Drug Evaluation	92
	5.5.1 In Vivo Models in Drug Discovery	93
	5.5.2 Models for Optimizing Therapy	94
5.6	Combination Therapy	95
5.7	Molecular Targeted Agents	97
5.8	Combining Signal Transduction Inhibitors	97
5.9	Future Directions	99
	References	100

**6 Pediatric Rhabdomyosarcoma:
Biology and Results of the North American
Intergroup Rhabdomyosarcoma Trials**
Alberto Pappo, Fred G. Barr,
Suzanne L. Wolden

6.1	Epidemiology	104
6.2	Pathology and Biology of Rhabdomyosarcoma	105
	6.2.1 Pathologic Classification of Rhabdomyosarcoma	105
	6.2.2 Chromosomal Translocations in Alveolar Rhabdomyosarcoma	106
	6.2.3 Allelic Loss of 11p15.5 in Embryonal Rhabdomyosarcoma	108
	6.2.4 Other Genetic Changes in Rhabdomyosarcoma	108
6.3	Clinical Presentation and Evaluation of Extent of Disease	110
	6.3.1 Head and Neck Region	110
	6.3.2 Genitourinary Tumors	110
	6.3.3 Extremity Tumors	110
	6.3.4 Trunk	110
	6.3.5 Other Sites	111
6.4	Staging	111
6.5	Prognostic Factors	114
6.6	Treatment	114
6.7	Role of Local Therapies	115
6.8	Multi-institutional Trials	117
	6.8.1 Clinical Group I	117
	6.8.2 Clinical Group II	120
	6.8.3 Clinical Group III	120
	6.8.4 Clinical Group IV	121
6.9	Management of Specific Tumor Sites	121
	6.9.1 Parameningeal Tumors	121
	6.9.2 Orbital Tumors	121
	6.9.3 Head and Neck Non-Orbital, Non-Parameningeal Tumors	122
	6.9.4 Parotid Tumors	122
	6.9.5 Extremity Tumors	123
	6.9.6 Paratesticular Rhabdomyosarcoma	123

6.9.7	Female Genital Tract Tumors	123
6.9.8	Bladder and Prostate Rhabdomyosarcoma	124
6.10	Other Sites	125
6.10.1	Biliary Tract Tumors	125
6.10.2	Perineal and Perianal Rhabdomyosarcoma	125
6.10.3	Pelvic and Retroperitoneal Rhabdomyosarcoma	125
6.11	Acute and Long Term Effects of Therapy	125
6.12	Future Directions	127
6.13	Outcome and Therapy of Relapse	127
	References	128

7 Non-Rhabdomyosarcoma

Soft Tissue Sarcomas

Sheri L. Spunt, Suzanne L. Wolden,
Deborah E. Schofield, Stephen X. Skapek

7.1	Epidemiology/Pathogenesis	134
7.1.1	Incidence	134
7.1.2	Risk Factors	134
7.2	Pathology/Molecular Pathology	135
7.2.1	Molecular Pathogenesis	137
7.2.2	Synovial Sarcoma and the SYT/SSX Translocation	139
7.2.3	Infantile Fibrosarcoma and ETV6-NTRK3	139
7.2.4	Rhabdoid Tumor and INI1	139
7.2.5	Inflammatory Myofibroblastic Tumor and ALK	140
7.2.6	Gastrointestinal Stromal Tumors and the KIT Transferase	140
7.2.7	Dermatofibrosarcoma Protuberans and PDGF	140
7.3	Histologic Classification	140
7.3.1	Synovial Sarcoma	141
7.3.2	Malignant Peripheral Nerve Sheath Tumor	142
7.3.3	Infantile Fibrosarcoma	142
7.3.4	Adult Type Fibrosarcoma	143
7.3.5	Rhabdoid Tumor	143
7.3.6	Inflammatory Myofibroblastic Tumor	144
7.3.7	Gastrointestinal Stromal Tumor	144
7.3.8	Infantile Hemangiopericytoma	145
7.3.9	Desmoplastic Small Round Cell Tumor	145
7.3.10	Grading Systems	146
7.4	Clinical Presentation and Diagnosis	146
7.4.1	Presenting Features	146
7.4.2	Differential Diagnosis	146
7.4.3	The Diagnostic Biopsy	147
7.4.4	Evaluation of Disease Extent	147
7.5	Prognostic Factors and Clinical Staging	148
7.5.1	Prognostic Factors	148
7.5.2	Clinical Staging	149

7.6	Treatment	150
7.6.1	Surgery	150
7.6.1.1	Surgical Management of the Primary Tumor	150
7.6.1.2	Surgical Management of Metastases	151
7.6.2	Radiation Therapy	151
7.6.2.1	Radiation Planning	152
7.6.2.2	Timing of Radiotherapy	153
7.6.2.3	Brachytherapy	153
7.6.2.4	New Technologies	154
7.6.2.5	Acute Side Effects of Radiotherapy	154
7.6.2.6	Long-Term Side Effects of Radiotherapy	154
7.6.3	Chemotherapy	155
7.6.3.1	Adjuvant Chemotherapy	155
7.6.3.2	Neoadjuvant Chemotherapy	156
7.6.3.3	Other Approaches to the Use of Standard Chemotherapy	157
7.6.3.4	High-Dose Chemotherapy	157
7.6.3.5	Novel Agents	157
7.6.3.6	Late Effects of Chemotherapy	158
7.7	Current Problems and Future Challenges	158
	References	158

8 Fibrous and Fibrohistiocytic Tumors

Diane Nam, Benjamin A. Alman

8.1	Fibrous and Fibrohistiocytic Tumors	164
8.2	Soft Tissue Fibrous Tumors	164
8.2.1	Epidemiology/Pathogenesis	165
8.2.2	Pathology/Molecular Biology	166
8.2.3	Clinical Presentation and Diagnosis	166
8.2.4	Prognostic Factors and Clinical Staging	167
8.2.4.1	Treatment of Fibrous Tumors	168
8.2.4.2	Current Problems and Future Challenges	168
8.3	Fibrohistiocytic Tumors	169
8.4	So-Called Fibrohistiocytic Tumors	169
8.4.1	Histologic Classification	169
8.4.2	Benign	170
8.4.2.1	Benign Fibrous Histiocytoma	170
8.4.2.1.1	Epidemiology/Pathogenesis	170
8.4.2.1.2	Pathology/Molecular Pathology	171
8.4.2.1.3	Clinical Presentation and Diagnosis	171
8.4.2.1.4	Prognostic Factors and Clinical Staging	171
8.4.2.2	Giant Cell Tumor of Tendon Sheath and Diffuse-Type Giant Cell Tumor	172
8.4.2.2.1	Epidemiology/Pathogenesis	172
8.4.2.2.2	Pathology/Molecular Pathology	172
8.4.2.2.3	Clinical Presentation and Diagnosis	172
8.4.2.2.4	Prognostic Factors and Clinical Staging	173

8.4.3	Intermediate	173
8.4.3.1	Giant Cell Fibroblastoma and Dermatofibrosarcoma Protuberans	173
8.4.3.1.1	<i>Epidemiology/Pathogenesis</i>	173
8.4.3.1.2	<i>Pathology/Molecular Pathology</i>	173
8.4.3.1.3	<i>Clinical Presentation and Diagnosis</i>	174
8.4.3.1.4	<i>Prognostic Factors and Clinical Staging</i>	174
8.4.3.2	Plexiform Fibrohistiocytic Tumor	174
8.4.3.2.1	<i>Epidemiology/Pathogenesis</i>	174
8.4.3.2.2	<i>Pathology/Molecular Pathology</i>	174
8.4.3.2.3	<i>Clinical Presentation and Diagnosis</i>	175
8.4.3.2.4	<i>Prognostic Factors and Clinical Staging</i>	175
8.4.3.3	Giant Cell Tumor of Soft Tissue	175
8.4.3.3.1	<i>Epidemiology/Pathogenesis</i>	175
8.4.3.3.2	<i>Pathology/Molecular Pathology</i>	175
8.4.3.3.3	<i>Clinical Presentation and Diagnosis</i>	175
8.4.3.3.4	<i>Prognostic Factors and Clinical Staging</i>	176
8.4.3.3.5	<i>Treatment of Fibrohistiocytic Tumors</i>	176
8.5	Current Problems and Future Challenges	176
	References	177

9 Ewing Sarcoma Family of Tumors

Carlos Rodriguez-Galindo, Fariba Navid,
Joseph Khoury, Matthew Krasin

9.1	Introduction	181
9.2	Epidemiology	182
9.3	Pathogenesis	182
9.4	Pathology	185
9.4.1	Microscopic Features	185
9.4.2	Molecular Pathology	186
9.5	Clinical Features	188
9.5.1	Extraosseous ESFT	189
9.5.2	Laboratory and Radiologic Evaluation	189
9.5.3	Prognostic Factors	190
9.6	Treatment	192
9.6.1	Treatment of Patients with Localized Disease	192
9.6.1.1	Four-Drug Regimens	192
9.6.1.2	Role of Ifosfamide and Etoposide	192
9.6.1.3	Increasing Dose Intensity	195
9.6.1.4	Current Studies	199

9.6.2	Local Control in ESFT	199
9.6.2.1	Surgical Therapy	200
9.6.2.2	Surgery and Adjuvant Radiation Therapy	201
9.6.2.3	Definitive Radiation Therapy	202
9.6.2.4	Role of Systemic Chemotherapy in Local Control	202
9.6.3	Treatment of Metastatic ESFT	203
9.6.4	Myeloablative Therapy with Hematopoietic Stem Cell Rescue for Metastatic ESFT	205
9.6.5	Second Malignancies	207
9.6.6	Recurrent ESFT	208
9.7	Future Developments	208
	References	211

10 Osteosarcoma

Paul A. Meyers

10.1	Incidence	219
10.2	Etiology/Pathogenesis	219
10.3	Molecular Biology	220
10.4	Pathology	221
10.5	Clinical Presentation and Natural History	222
10.6	Diagnostic Evaluation	222
10.7	Biopsy	223
10.8	Staging	223
10.9	Prognostic Factors	223
10.10	Treatment	225
10.11	Surgery	227
10.12	Radiation Therapy	227
10.13	Recurrent Disease	228
10.14	Future Directions	228
	References	228

Subject Index	235
--------------------------------	-----